Official Course
Description: MCCCD Approval: 11-22-2005 |
||
HCE242 2006
Spring – 2011 Summer II |
L+L 6.0 Credit(s) 9.0 Period(s) 8.1 Load Occ |
|
Clinical Hematology and Hemostasis
|
||
Examines the anatomy and physiology of the hematopoietic and hemostasis systems, hematology and hemostasis case studies, anemia categories, and thrombocyte, hemostatic, and malignant and nonmalignant leukocyte disorders. Emphasis on interpreting, evaluating, and reporting hematology and hemostasis results, anticoagulant therapy, morphology, peripheral smear correlation with analyzer results and patient condition, erythrocyte indices, collection techniques, specimen handling, calibration, and quality control. Methods of analysis on hematology and hemostasis analyzers, and preventive maintenance. Prerequisites: Acceptance into the Clinical Laboratory Sciences program or permission of the Program Director. |
||
|
Go to Competencies Go to Outline
MCCCD Official Course Competencies: |
|
|
|
HCE242 2006 Spring – 2011 Summer II |
Clinical Hematology and
Hemostasis |
1. |
Differentiate between the anatomy and physiology of the normal human hematopoietic and hemostatic system. (I, XII) |
2. |
Determine collection techniques and specimen handling for peripheral blood specimens, bone marrow, and specimens for hemostasis (coagulation) testing. (II) |
3. |
Calculate and correlate erythrocyte indices and absolute and relative counts. (III) |
4. |
Evaluate normal and abnormal peripheral blood cells and morphology. (III-V) |
5. |
Correlate analyzer results with peripheral smears and patient condition. (IV) |
6. |
Assess anemia categories based on hematologic analysis results. (V) |
7. |
Appraise various nonmalignant leukocyte disorders. (VI) |
8. |
Appraise various malignant disorders of leukocytes. (VII) |
9. |
Appraise various thrombocyte abnormalities. (VIII) |
10. |
Apply standard laboratory procedures in interpreting, evaluating, and reporting hematology and hemostasis results. (IX) |
11. |
Manage preventive maintenance and troubleshooting techniques on hematology and hemostasis instruments. (IX) |
12. |
Assay and evaluate patient samples on hematology and hemostasis analyzers. (IX) |
13. |
Perform and interpret calibration and quality control on instruments used in hematology and hemostasis testing. (IX) |
14. |
Evaluate the principles of method analyses in hematologic and hemostasis testing. (IX, XI, XIII) |
15. |
Evaluate hematology and hemostasis case studies. (X) |
16. |
Describe and evaluate disorders of hemostasis. (XIV) |
17. |
Evaluate laboratory tests used to monitor anticoagulant therapy. (XV) |
|
|
Go to Description Go to top of Competencies
MCCCD Official Course Outline: |
|
|
|
HCE242 2006 Spring – 2011 Summer II |
Clinical Hematology and
Hemostasis |
I. Normal Hematopoiesis and Hemostasis A. Fetus B. Infant and Child C. Adult D. Reticuloendothelial system II. Specimen Collection and Handling Techniques A. Peripheral blood B. Bone marrow C. Hemostasis testing D. Other III. Erythropoiesis A. Maturation sequence B. Regulatory factors C. Hemoglobin 1. Structure 2. Function 3. Globin synthesis a.
b. Genetic variants 4. Altered derivatives 5. Methods of analysis D. Catabolization 1. Extravascular 2. Intravascular E. Erythrocyte analysis 1. Counts a. Manual b. Automated 2. Hematocrits 3. Indices 4. Reticulocytes a. Manual b. Automated 5. Peripheral Smear Evaluation a. Normal morphology b. Abnormal morphology 6. Reference ranges a. Neonates b. Children c. Adults IV. Leukopoiesis A. Maturation sequences B. Regulatory factors C. Leukocyte analysis/counts 1. Manual 2. Automated 3. Relative 4. Absolute D. Peripheral smear evaluation 1. Normal cells 2. Abnormal cells 3. Performing differentials a. Manual b. Automated E. Reference ranges 1. Neonates 2. Children 3. Adults V. Erythrocyte Disorders A. Anemia 1. Clinical signs and symptoms 2. Hematologic findings a. Hypochromic anemias b. Megaloblastic anemias c. Hypoproliferative anemias d. Hemolytic anemias 3. Morphology changes B. Erythrocytosis 1. Polycythemias 2. Other VI. Nonmalignant Leukocyte Disorders A. Quantitative changes B. Qualitative changes 1. Acquired 2. Inherited VII. Neoplastic Leukocyte Disorders A. Leukemia 1. Risk factors 2. Diagnosis 3. Treatment 4. FAB (French-American-British) classification B. Acute leukemias C. Myelodysplastic syndromes D. Chronic myeloproliferative disorders E. Chronic lymphoproliferative disorders F. Plasma cell disorders G. Lymphomas VIII. Thrombopoiesis A. Maturation sequence B. Regulatory factors C. Thrombocyte analysis 1. Quantitative a. Manual b. Automated 2. Qualitative 3. Morphology IX. Automation for Hematology and Hemostasis A. Principles of method analyses B. Calibration C. Quality control D. Proficiency testing E. Preventive maintenance F. Troubleshooting G. Assaying patient samples 1. Evaluate results 2. Correlate and interpret results 3. Report results a. Autoverification b. Other H. Documentation X. Case Studies A. Hematologic B. Thrombopoietic C. Hemostatic XI. Miscellaneous Hematology Tests A. Sickle cell screening B. Hemoglobin electrophoresis C. Flow cytometry D. Erythrocyte sedimentation rates (ESR) E. Osmotic fragility F. Kleihauer-Betke stain G. Cytochemical stains 1. Romanowsky - type 2. Enzymes 3. Esterases 4. Dyes XII. Hemostasis A. Primary hemostasis 1. Vasculature 2. Platelets B. Secondary hemostasis 1. Plasma coagulation factors 2. Intrinsic, extrinsic and common pathways C. Inhibitors of hemostasis D. Fibrinolysis XIII. Coagulation Tests A. Prothrombin Time (PT) test B. Activated Partial Thromboplastin Time (APTT) C. Thrombin clotting time D. Fibrinogen assay E. Factor assays F. D-Dimer G. Fibrinogen degradation products (FDP) Assay H. Mixing study J. Dilute Russell viper venom time (DRVVT) K. Protein C and S L. Other XIV. Disorders of Hemostasis A. Primary B. Secondary 1. Inherited 2. Acquired C. Fibrinolysis 1. Disseminated intravascular coagulation (DIC) 2. Other D. Recurrent thrombosis (thrombophilia) XV. Anticoagulant Therapy A. Antiplatelet agents B. Heparin 1. Unfractionated 2. Low molecular weight heparin (LMWH) C. Warfarin/Coumadin D. Other drugs |